share_log

Expensify And 2 Other Stocks Under $2 Insiders Are Buying

Expensify And 2 Other Stocks Under $2 Insiders Are Buying

Expensify和其他2美元以下的股票内部人士正在买入
Benzinga ·  04/22 07:38

The Dow Jones index closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道琼斯指数周五收盘上涨超过200点。当内部人士购买或出售股票时,这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将此视为他们整体投资或交易决策的一个因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是细价股最近几笔值得注意的内幕交易。欲了解更多信息,请访问Benzinga的内幕交易平台。

BioCardia

BioCardia

  • The Trade: BioCardia, Inc (NASDAQ:BCDA) CEO and President Peter Altman acquired a total of 2,750 shares an average price of $0.37. To acquire these shares, it cost around $1,013.
  • What's Happening: On March 27, BioCardia posted a narrower-than-expected quarterly loss.
  • What BioCardia Does: BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs.
  • 交易:BioCardia, Inc(纳斯达克股票代码:BCDA)首席执行官兼总裁彼得·奥特曼共收购了2750股股票,平均价格为0.37美元。收购这些股票的成本约为1,013美元。
  • 发生了什么:3月27日,BioCardia公布的季度亏损低于预期。
  • BioCardia 做什么:BioCardia Inc 是一家处于临床阶段的公司,开发细胞和细胞衍生疗法,用于治疗医疗需求未得到满足的心血管和肺部疾病。

Expensify

昂贵化

  • The Trade: Expensify, Inc. (NASDAQ:EXFY) 10% owner SF Roofdeck GP LLC acquired a total of 143,639 shares at at an average price of $1.51. To acquire these shares, it cost around $216,222.
  • What's Happening: On Feb. 22, Expensify reported better-than-expected fourth-quarter adjusted EPS results.
  • What Expensify Does: Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money.
  • 交易:Expensify, Inc.(纳斯达克股票代码:EXFY)10%的所有者SF Roofdeck GP LLC共收购了143,639股股票,平均价格为1.51美元。收购这些股票的成本约为216,222美元。
  • 发生了什么:2月22日,Expensify公布的第四季度调整后每股收益好于预期。
  • Expensify的作用:Expensify Inc是一个基于云的费用管理软件平台,可帮助各种企业简化资金管理方式。

Clearside Biomedical

克利尔赛德生物医

  • The Trade: Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Anthony S Gibney acquired a total of 100,000 shares at an average price of $1.30. The insider spent around $129,665 to buy those shares.
  • What's Happening: On April 16, Clearside Biomedical named seasoned biotechnology executive Anthony S. Gibney to its Board of Directors.
  • What Clearside Biomedical Does: Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company.
  • 交易:Clearside Biomedical, Inc.(纳斯达克股票代码:CLSD)董事安东尼·吉布尼共收购了10万股股票,平均价格为1.30美元。知情人士花费了约129,665美元购买了这些股票。
  • 发生了什么:4月16日,Clearside Biomedical任命了经验丰富的生物技术高管安东尼·吉布尼为董事会成员。
  • Clearside Biomedical的所作所为:Clearside Biomedical Inc是一家总部位于美国的临床生物制药公司。

Read More: Albertsons Companies, Nucor And 3 Stocks To Watch Heading Into Monday

阅读更多:周一艾伯森公司、纽柯和三只股票值得关注

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发